Aim: The aim of this retrospective study was to investigate the efficacy and safety of ramucirumab treatment under real-world conditions and to clarify the role of albumin-bilirubin (ALBI) score in predicting outcomes.
Methods: Between June 2019 and May 2020, a total of 16 patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab in Gunma Saiseikai Maebashi Hospital and its affiliated hospitals was included.
Results: The median age was 71 (interquartile range [IQR] 65-74) years old, and 12 patients (75.0%) were male. The modified ALBI (mALBI) grade was 1, 2a, and 2b at baseline in 4 (25.0%), 3 (18.8%), and 9 patients (56.3%), respectively. The Barcelona Clinic Liver Cancer stage was intermediate and advanced stage in 1 (6.3%) and 15 patients (93.8%), respectively. The serum α-fetoprotein at baseline was 4,911 (IQR 2,091-17,377) ng/mL. The disease control rate in patients with mALBI grade1 + 2a was significantly higher than in those with mALBI grade 2b (100 vs. 28.6%, p = 0.028). The patients with mALBI grade 1 + 2a had a significantly better overall survival (OS) and longer progression-free survival (PFS) than those with mALBI grade 2b (median OS 6.7 vs. 3.0 months; p = 0.036, median PFS 7.5 vs. 1.4 months; p = 0.002). The number of cycles of ramucirumab treatment was significantly correlated with the ALBI score (r = -0.452, p = 0.030). The patients with mALBI grade 1 + 2a showed a low incidence of adverse events (AEs) and discontinuation due to AEs.
Conclusions: Advanced HCC patients with mALBI grade 1 + 2a may be a good indication for ramucirumab treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000511734 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models.
J Gastroenterol Hepatol
January 2025
Department of Nursing, Gifu Kyoritsu University, Ogaki, Japan.
Aim: This study aimed to compare the prognostic performance of the risk models for patients with hepatocellular carcinoma (HCC) receiving atezolizumab and bevacizumab (Atez/Bev) as first-line treatment.
Methods: Among 449 patients included in this retrospective multicenter study, we compared the prognostic performance of 13 risk models for the 12-month and 18-month survival status using area under the curve (AUC), net reclassification improvement (NRI), and relative integrated discrimination improvement (IDI) analysis. We also constructed a calibration plot to assess the fitness of each model.
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study.
Liver Cancer
December 2024
Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Introduction: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with treatment outcomes closely tied to liver function. This study evaluates the prognostic utility of the albumin-bilirubin (ALBI) score compared to the traditional Child-Pugh (CP) grading, leveraging real-world evidence from a large-scale, multi-center database.
Methods: The Liver Cancer IN Korea (LINK) research network, a multi-center initiative, retrospectively collected electronic health records from three academic hospitals in South Korea, encompassing HCC patients diagnosed between 2015 and 2020.
Heterogeneous development of liver fibrosis in chronic hepatitis C patients; assessment by extracellular volume fraction map generated from routine clinical CT data.
Eur J Radiol
January 2025
Department of Radiology, Fukuoka University, 7-45-1 Nanakuma, Jonanku, Fukuoka, Japan. Electronic address:
Objectives: To clarify the heterogeneous development of liver fibrosis in patients with chronic hepatitis C (CHC) using extracellular volume fraction (ECV) map obtained from routine clinical CT data.
Methods: Between November 2012 and July 2020, patients with CHC were retrospectively recruited who had undergone four-phase CT and MR elastography (MRE) within one year. Patients were divided into 4 grades to represent different cirrhotic/fibrotic stage, using two different methods; one based on liver stiffness measured by MRE (MRE model), and the other by mALBI grades (mALBI model).
99mTc-GSA scintigraphy and modified albumin-bilirubin score can be complementary to ICG for predicting posthepatectomy liver failure.
BMC Surg
November 2024
Department of Surgery, Fujita Health University, 1-98 Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
Article Synopsis
- - The study analyzed the effectiveness of various hepatic functional tests, specifically modified ALBI score, indocyanine green clearance (ICG-R15), and 99mTc-galactosyl human serum albumin (LHL15) scintigraphy, in predicting posthepatectomy liver failure (PHLF) among patients undergoing liver surgery.
- - Out of 413 patients studied, 19% experienced PHLF, with major hepatectomy, mALBI grade, ICG-R15, and presence of esophagogastric varices identified as significant independent risk factors for developing this complication.
- - The results suggested that LHL15, esophagogastric varices assessment, and the mALBI
Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular Carcinoma.
Acta Med Okayama
October 2024
Department of Nursing, Gifu Kyoritsu University.
We previously found that "albumin grade", formerly called the "ALBS grade," demonstrated significant capability for prognostic stratification in hepatocellular carcinoma (HCC) patients treated with lenvatinib. The purpose of the present study was to compare the performance of the albumin grade with that of the modified albumin-bilirubin (mALBI) grade in predicting overall survival of HCC patients with different BCLC stages and treatment types. We enrolled 7,645 Japanese patients newly diagnosed with HCC using the Akaike information criteria (AIC), likelihood ratio, and C-index in different Barcelona Clinic Liver Cancer (BCLC) stages and treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!